Chronic hepatitis B is a persistent and progressive inflammatory liver disease caused by infection with the hepatitis B virus.
More than 240 million individuals are infected with hepatitis B virus worldwide and hepatitis B accounts for an estimated 650,000 deaths annually.
Dr Joao Serigado and colleagues investigate therapies that are under evaluation for the management of chronic hepatitis B.
Approximately up to 30% of chronically infected patients will develop complications of hepatitis B virus infection including, but not limited to, liver cirrhosis, end-stage liver disease, and hepatocellular carcinoma.
|Approximately up to 30% of chronically infected patients will develop complications |
|European Journal of Gastroenterology & Hepatology|
Currently approved therapies have improved clinical outcomes, but have a considerable side-effect profile, elevated cost, and a finite course of treatment.
This has led to a growing interest in research for new therapies.
As the mechanisms for hepatitis B virus replication are becoming better understood, new potential targets have been discovered, leading to the development of new therapies.
Dr Serigado's team concludes, "In this article, we describe the promising therapies that are under evaluation, showing their mechanisms of action, effects, and stage of development."